Directori de persones
Manuel Portero Otin

Manuel Portero Otin

Grau: Doctor/a

973 702 408
manuel.portero(ELIMINAR)@udl.cat

ResearcherID: http://www.researcherid.com/rid/B-7122-2009

Grups

Publicacions

  • Bellmunt, MJ; PORTERO, M; Pamplona, R; MUNTANER, M; PRAT, J

    Age-related fluorescence in rat lung collagen.

    Lung 173 177-185. .

  • PorteroOtin, M; NAGARAJ, RH; MONNIER, VM

    CHROMaTOGRaPHIC EVIDENCE FOR PYRRaLINE FORMaTION DURING PROTEIN GLYCaTION IN-VITRO aND IN-VIVO

    Biochimica Et Biophysica Acta-Protein Structure And Molecular Enzymology 1247 74-80. .

    [doi:10.1016/0167-4838(94)00209-Y]

  • Pamplona R; Bellmunt MJ; Portero M; Riba D; Prat J

    Chromatographic evidence for Amadori product formation in rat liver aminophospholipids.

    LIFE SCIENCES 57 873-879. .

  • Pamplona, R; PORTERO, M; Bellmunt, MJ; Prat, J

    RELaTIONSHIP BETWEEN SOLUBILITY aND FLUORESCENCE DUE TO GLYCOXIDaTION PRODUCTS IN RaT LUNG COLLaGEN

    FREE RADICAL BIOLOGY AND MEDICINE 15 539-539. .

    [doi:10.1016/0891-5849(93)90441-V]

  • Pamplona, R; Bellmunt, MJ; PORTERO, M; Prat, J

    Mechanisms of glycation in atherogenesis.

    MED HYPOTHESES 40 174-181. .

    [doi:10.1016/0306-9877(93)90207-7]

Projectes

  • Spanish Minor Stroke Perfusion Initiative: SMS-P Initiative
  • SEED-ALS: Synergizing Efforts to Develop and Accelerate Breakthroughs in ALS Research
  • Natural microbicides from rice against current and emerging infectious diseases
  • Humanised mouse models to study ATG4B cryptic exon involvement in ALS pathogenesis and its potential as disease biomarker (Hum4ALS)
  • Targeting cryptic exons as biomarkers and ALS therapy
  • Desregulacion de TDP-43,eje clave en la ELA: Caracterización de firmas lipidómicas, transcriptómicas y autofágicas en muestras específicas de pacientes para biomarcadores y reposicionamiento
  • Comprehensive Roadmap and Preclinical Evaluation of Antisense Oligonucleotides (ASOs) Regulatory Development and Toxicological Assessment for ALS Treatment
  • The role of defects in mitochondria-associated ER membranes (MAM) to Amyotrophic Lateral Sclerosis
  • Perspectivas clínicas de la biología de sistemas aplicada al análisis de placas carotídeas humanas: ILER-CAROTID
  • Metabolismo lipidico intracelular, procesamiento de ARNm y estrés celular en la encrucijada de la fisiopatología de la esclerosis lateral amiotrófica
  • Identification of compounds for inhibition of ACE2 membrane expression
  • Reposicionamiento terapéutico dirigido a inhibición de expresión de ACE2 y de proteolisis de trímero S viral